{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:18:29Z","timestamp":1793305109458,"version":"4.5.0"},"reference-count":85,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100030760","name":"Bayer United States","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030760","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>The mineralocorticoid receptor (MR) is a nuclear transcription factor that plays a critical role in regulating fluid, electrolytes, blood pressure, and hemodynamic stability. In conditions such as chronic kidney disease (CKD) and heart failure (HF), MR overactivation leads to increased salt and water retention, inflammatory and fibrotic gene expression, and organ injury. The MR is essential for transcriptional regulation and is implicated in metabolic, proinflammatory, and pro-fibrotic pathways. It is widely expressed in various cell types throughout the body, including the gastrointestinal tract, heart, brain, kidneys, immune cells, and vasculature. Animal studies suggest that MR activation induces oxidative stress in the kidneys and mediates renal inflammation and fibrosis. Immune cell-specific deletion of MR has shown protection against cardiac fibrosis, indicating the MR's role in pathological remodeling. In vascular smooth muscle cells, the MR regulates vascular tone and vasoconstriction.<\/jats:p>\n                  <jats:p>Mineralocorticoid receptor antagonists (MRAs) can be categorized based on their chemical structure as either steroidal or nonsteroidal. Steroidal MRAs (sMRA), such as spironolactone and eplerenone, have demonstrated cardiovascular benefits but are limited by hyperkalemia, gynecomastia, and sexual dysfunction. Nonsteroidal MRAs (nsMRA) have shown promise in preclinical studies and clinical trials. They offer a promising alternative by effectively blocking MR without hormone-like effects, potentially improving cardiovascular and renal disease management.<\/jats:p>\n                  <jats:p>Further education is necessary regarding the significance of MRA utilization in CKD and HF, balancing benefits with the risk of hyperkalemia. This risk could be mitigated by combining MRAs with potassium-binding agents. Studies are underway to explore the synergistic effects between nsMRAs and other agents, such as SGLT-2i inhibitors and Glucagon-like peptide-1 agonists, to optimize cardiorenal outcomes.<\/jats:p>\n                  <jats:p>Overall, MR overactivation remains a significant therapeutic target, with nsMRAs showing promise as pivotal therapies in CKD and HF management. This review highlights the evolving landscape of MR-targeted therapies, their molecular mechanisms, and clinical implications in cardiorenal diseases.<\/jats:p>","DOI":"10.1093\/ckj\/sfae346","type":"journal-article","created":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T15:24:08Z","timestamp":1732116248000},"source":"Crossref","is-referenced-by-count":25,"title":["Clinical implications of mineralocorticoid receptor overactivation"],"prefix":"10.1093","volume":"18","author":[{"given":"Christopher","family":"El Mouhayyar","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Massachusetts General Hospital , Boston, MA ,","place":["USA"]},{"name":"Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Chhikara","sequence":"additional","affiliation":[{"name":"Lal Bahadur Shastri Hospital , Delhi ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyao","family":"Tang","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Massachusetts General Hospital , Boston, MA ,","place":["USA"]},{"name":"Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar U","family":"Nigwekar","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Massachusetts General Hospital , Boston, MA ,","place":["USA"]},{"name":"Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,21]]},"reference":[{"key":"2025052712311062600_bib1","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"key":"2025052712311062600_bib2","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/cphy.c130044","article-title":"The multifaceted mineralocorticoid receptor","volume":"4","author":"Gomez-Sanchez","year":"2014","journal-title":"Compr Physiol"},{"key":"2025052712311062600_bib3","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1053\/j.ajkd.2022.04.016","article-title":"Mineralocorticoid receptor activation, and CKD: a review of evolving treatment paradigms","volume":"80","author":"Epstein","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"2025052712311062600_bib4","doi-asserted-by":"publisher","first-page":"T125","DOI":"10.1530\/JOE-16-0600","article-title":"30 years of the mineralocorticoid receptor: mineralocorticoid receptor antagonists: 60 years of research and development","volume":"234","author":"Kolkhof","year":"2017","journal-title":"J Endocrinol"},{"key":"2025052712311062600_bib5","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ijwd.2020.05.002","article-title":"Retrospective analysis of adverse events with spironolactone in females reported to the United States Food and Drug Administration","volume":"6","author":"Wang","year":"2020","journal-title":"Int J Womens Dermatol"},{"key":"2025052712311062600_bib6","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/164_2016_76","article-title":"Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside","volume":"243","author":"Kolkhof","year":"2017","journal-title":"Handb Exp Pharmacol"},{"key":"2025052712311062600_bib7","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.mce.2011.07.020","article-title":"Tissue-specific modulation of mineralocorticoid receptor function by 11\u03b2-hydroxysteroid dehydrogenases: an overview","volume":"350","author":"Odermatt","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"2025052712311062600_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2017.00313","article-title":"Mineralocorticoid receptor signaling as a therapeutic target for renal and cardiac fibrosis","volume":"8","author":"Tesch","year":"2017","journal-title":"Front Pharmacol"},{"key":"2025052712311062600_bib9","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.mce.2011.06.025","article-title":"Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics","volume":"350","author":"Kolkhof","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"2025052712311062600_bib10","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.1111\/bph.15719","article-title":"Approaches towards tissue-selective pharmacology of the mineralocorticoid receptor","volume":"179","author":"Clarisse","year":"2022","journal-title":"Br J Pharmacol"},{"key":"2025052712311062600_bib11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11906-016-0649-2","article-title":"Finerenone: a new mineralocorticoid receptor antagonist without hyperkalemia: an opportunity in patients with CKD?","volume":"18","author":"Haller","year":"2016","journal-title":"Curr Hypertens Rep"},{"key":"2025052712311062600_bib12","doi-asserted-by":"publisher","first-page":"105859","DOI":"10.1016\/j.phrs.2021.105859","article-title":"Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders \u2013 new perspectives for combination therapy","volume":"172","author":"Kolkhof","year":"2021","journal-title":"Pharmacol Res"},{"key":"2025052712311062600_bib13","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1161\/01.HYP.0000255636.11931.a2","article-title":"Podocyte as the target for aldosterone","volume":"49","author":"Shibata","year":"2007","journal-title":"Hypertension"},{"key":"2025052712311062600_bib14","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1172\/JCI118867","article-title":"Role of aldosterone in the remnant kidney model in the rat","volume":"98","author":"Greene","year":"1996","journal-title":"J Clin Invest"},{"key":"2025052712311062600_bib15","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nrneph.2013.110","article-title":"Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis","volume":"9","author":"Brown","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"2025052712311062600_bib16","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1046\/j.1523-1755.2003.00929.x","article-title":"Aldosterone\/salt induces renal inflammation and fibrosis in hypertensive rats","volume":"63","author":"Blasi","year":"2003","journal-title":"Kidney Int"},{"key":"2025052712311062600_bib17","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1161\/01.HYP.0000118519.66430.22","article-title":"Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone\/salt-induced hypertensive rats","volume":"43","author":"Nishiyama","year":"2004","journal-title":"Hypertension"},{"key":"2025052712311062600_bib18","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1681\/ASN.2006090975","article-title":"Impairment of sodium balance in mice deficient in renal principal cell mineralocorticoid receptor","volume":"18","author":"Ronzaud","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"2025052712311062600_bib19","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s00424-015-1785-2","article-title":"Adult nephron-specific MR-deficient mice develop a severe renal PHA-1 phenotype","volume":"468","author":"Canonica","year":"2016","journal-title":"Pflugers Arch"},{"key":"2025052712311062600_bib20","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1681\/ASN.2015070815","article-title":"Direct and indirect mineralocorticoid effects determine distal salt transport","volume":"27","author":"Terker","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"2025052712311062600_bib21","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/nrneph.2012.191","article-title":"The role of the kidney in regulating arterial blood pressure","volume":"8","author":"Wadei","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"2025052712311062600_bib22","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s40620-019-00684-1","article-title":"Recent insights into sodium and potassium handling by the aldosterone-sensitive distal nephron: a review of the relevant physiology","volume":"33","author":"Rossi","year":"2020","journal-title":"J Nephrol"},{"key":"2025052712311062600_bib23","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1001\/archinternmed.2010.362","article-title":"Serum and dietary potassium and risk of incident type 2 diabetes: the atherosclerosis risk in communities (ARIC) study","volume":"170","author":"Chatterjee","year":"2010","journal-title":"Arch Intern Med"},{"key":"2025052712311062600_bib24","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa032922","article-title":"Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes","volume":"350","author":"Gloyn","year":"2004","journal-title":"N Engl J Med"},{"key":"2025052712311062600_bib25","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1161\/01.HYP.35.5.1078","article-title":"Local angiotensin II and transforming growth factor-beta1 in renal fibrosis of rats","volume":"35","author":"Sun","year":"2000","journal-title":"Hypertension"},{"key":"2025052712311062600_bib26","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1046\/j.1523-1755.2000.00277.x","article-title":"Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo","volume":"58","author":"Brown","year":"2000","journal-title":"Kidney Int"},{"key":"2025052712311062600_bib27","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1161\/01.HYP.0000174593.88899.68","article-title":"Aldosterone stimulates collagen gene expression and synthesis via activation of ERK1\/2 in rat renal fibroblasts","volume":"46","author":"Nagai","year":"2005","journal-title":"Hypertension"},{"key":"2025052712311062600_bib28","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.gene.2013.08.047","article-title":"Aldosterone stimulates fibronectin synthesis in renal fibroblasts through mineralocorticoid receptor-dependent and independent mechanisms","volume":"531","author":"Chen","year":"2013","journal-title":"Gene"},{"key":"2025052712311062600_bib29","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1159\/000339500","article-title":"Aldosterone induces kidney fibroblast proliferation via activation of growth factor receptors and PI3K\/MAPK signalling","volume":"120","author":"Huang","year":"2012","journal-title":"Nephron Exp Nephrol"},{"key":"2025052712311062600_bib30","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/S0140-6736(58)92163-9","article-title":"Experimental production of endomyocardial fibrosis","volume":"271","author":"Selye","year":"1958","journal-title":"Lancet North Am Ed"},{"key":"2025052712311062600_bib31","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1161\/HYPERTENSIONAHA.109.131110","article-title":"Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone\/salt-induced cardiac fibrosis and increased blood pressure","volume":"54","author":"Rickard","year":"2009","journal-title":"Hypertension"},{"key":"2025052712311062600_bib32","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.cjca.2023.01.013","article-title":"T-cell mineralocorticoid receptor deficiency attenuates pathologic ventricular remodelling after myocardial infarction","volume":"39","author":"Wang","year":"2023","journal-title":"Can J Cardiol"},{"key":"2025052712311062600_bib33","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1161\/CIRCULATIONAHA.110.983023","article-title":"Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction","volume":"123","author":"Fraccarollo","year":"2011","journal-title":"Circulation"},{"key":"2025052712311062600_bib34","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1161\/HYPERTENSIONAHA.112.203158","article-title":"Cardiomyocyte mineralocorticoid receptors are essential for deoxycorticosterone\/salt-mediated inflammation and cardiac fibrosis","volume":"60","author":"Rickard","year":"2012","journal-title":"Hypertension"},{"key":"2025052712311062600_bib35","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1161\/HYPERTENSIONAHA.115.05981","article-title":"Cardiomyocyte mineralocorticoid receptor activation impairs acute cardiac functional recovery after ischemic insult","volume":"66","author":"Bienvenu","year":"2015","journal-title":"Hypertension"},{"key":"2025052712311062600_bib36","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1161\/STROKEAHA.110.598441","article-title":"Myeloid-specific deletion of the mineralocorticoid receptor reduces infarct volume and alters inflammation during cerebral ischemia","volume":"42","author":"Frieler","year":"2011","journal-title":"Stroke"},{"key":"2025052712311062600_bib37","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1681\/ASN.2012111094","article-title":"Myeloid mineralocorticoid receptor activation contributes to progressive kidney disease","volume":"25","author":"Huang","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"2025052712311062600_bib38","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1172\/JCI41080","article-title":"Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice","volume":"120","author":"Usher","year":"2010","journal-title":"J Clin Invest"},{"key":"2025052712311062600_bib39","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1681\/ASN.2016040477","article-title":"Benefit of mineralocorticoid receptor antagonism in AKI: role of vascular smooth muscle Rac1","volume":"28","author":"Barrera-Chimal","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2025052712311062600_bib40","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1038\/nm.2891","article-title":"Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors","volume":"18","author":"McCurley","year":"2012","journal-title":"Nat Med"},{"key":"2025052712311062600_bib41","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1161\/01.HYP.0000154365.30593.d3","article-title":"Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-src","volume":"45","author":"Callera","year":"2005","journal-title":"Hypertension"},{"key":"2025052712311062600_bib42","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1161\/01.ATV.0000258414.59393.89","article-title":"Mineralocorticoid receptor activation promotes vascular cell calcification","volume":"27","author":"Jaffe","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2025052712311062600_bib43","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"key":"2025052712311062600_bib44","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/s00125-023-06031-1","article-title":"Mineralocorticoid receptor overactivation: targeting systemic impact with non-steroidal mineralocorticoid receptor antagonists","volume":"67","author":"Savarese","year":"2024","journal-title":"Diabetologia"},{"key":"2025052712311062600_bib45","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.mce.2003.10.005","article-title":"The evolution of aldosterone antagonists","volume":"217","author":"Garthwaite","year":"2004","journal-title":"Mol Cell Endocrinol"},{"key":"2025052712311062600_bib46","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2025052712311062600_bib47","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"2025052712311062600_bib48","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"2025052712311062600_bib49","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1093\/eurheartj\/ehu164","article-title":"Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: The Randomized Double-Blind Reminder Study","volume":"35","author":"Montalescot","year":"2014","journal-title":"Eur Heart J"},{"key":"2025052712311062600_bib50","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1016\/j.jacc.2016.02.033","article-title":"Early aldosterone blockade in acute myocardial infarction: the ALBATROSS randomized clinical trial","volume":"67","author":"Beygui","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2025052712311062600_bib51","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"2025052712311062600_bib52","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"2025052712311062600_bib53","volume-title":"Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction, SPIRRIT-HFPEF","author":"Uppsala University","year":"2023"},{"key":"2025052712311062600_bib54","volume-title":"Spironolactone in the Treatment of Heart Failure- A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Interventional Phase III Study to Determine Efficacy and Safety of Spironolactone on the Composite Endpoint of Recurrent Heart Failure Hospitalizations and Cardiovascular Death in Patients with Heart Failure with Mid-Range or Preserved Ejection Fraction","author":"Pieske","year":"2021"},{"key":"2025052712311062600_bib55","volume-title":"ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial (ALCHEMIST), Phase III b","author":"University Hospital, Brest","year":"2023"},{"key":"2025052712311062600_bib56","author":"Nesbitt","year":"2023"},{"key":"2025052712311062600_bib57","volume-title":"Aldosterone bloCkade for Health Improvement EValuation in End-Stage Renal Disease","author":"Population Health Research Institute","year":"2023"},{"key":"2025052712311062600_bib58","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1002\/ejhf.900","article-title":"Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF","volume":"19","author":"Ferreira","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2025052712311062600_bib59","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.ejheart.2007.09.008","article-title":"Is the gap between guidelines and clinical practice in heart failure treatment being filled? Insights from the IMPACT RECO survey","volume":"9","author":"de Groote","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"2025052712311062600_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2013.00115","article-title":"PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy","volume":"4","author":"Orena","year":"2013","journal-title":"Front Pharmacol"},{"key":"2025052712311062600_bib61","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1097\/MNH.0000000000000147","article-title":"Nonsteroidal antagonists of the mineralocorticoid receptor","volume":"24","author":"Kolkhof","year":"2015","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2025052712311062600_bib62","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1161\/HYPERTENSIONAHA.120.15199","article-title":"Mineralocorticoid receptor antagonists for hypertension management in advanced chronic kidney disease","volume":"76","author":"Bakris","year":"2020","journal-title":"Hypertension"},{"key":"2025052712311062600_bib63","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1161\/HYPERTENSIONAHA.121.17073","article-title":"Effect of KBP-5074 on blood pressure in advanced chronic kidney disease: results of the BLOCK-CKD study","volume":"78","author":"Bakris","year":"2021","journal-title":"Hypertension"},{"key":"2025052712311062600_bib64","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1080\/13543784.2017.1274732","article-title":"Discontinued drug therapies to treat diabetes in 2015","volume":"26","author":"Hedrington","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"2025052712311062600_bib65","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3294","article-title":"Balcinrenone plus dapagliflozin in patients with heart failure and chronic kidney disease: results from the phase 2b MIRACLE trial","volume":"26","author":"Lam","journal-title":"Eur J Heart Fail"},{"key":"2025052712311062600_bib66","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/cpdd.855","article-title":"Phase 1 studies to define the safety, tolerability, and pharmacokinetic and pharmacodynamic profiles of the nonsteroidal mineralocorticoid receptor antagonist apararenone in healthy volunteers","volume":"10","author":"Nakamura","year":"2021","journal-title":"Clin Pharm Drug Dev"},{"key":"2025052712311062600_bib67","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s10157-020-01963-z","article-title":"Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose\u2013response study and open-label extension study","volume":"25","author":"Wada","year":"2021","journal-title":"Clin Exp Nephrol"},{"key":"2025052712311062600_bib68","author":"Pipeline | R&D | Mitsubishi Tanabe Pharma Corporation"},{"key":"2025052712311062600_bib69","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41371-020-0377-6","article-title":"Esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker (MRB) in hypertension and chronic kidney disease","volume":"35","author":"Wan","year":"2021","journal-title":"J Hum Hypertens"},{"key":"2025052712311062600_bib70","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","article-title":"Double-blind randomized phase 3 study comparing Esaxerenone (CS-3150) and Eplerenone in patients with essential hypertension (ESAX-HTN Study)","volume":"75","author":"Ito","year":"2020","journal-title":"Hypertension"},{"key":"2025052712311062600_bib71","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.2215\/CJN.06870520","article-title":"Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial","volume":"15","author":"Ito","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025052712311062600_bib72","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1093\/eurjhf\/hfs061","article-title":"Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease","volume":"14","author":"Pitt","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"2025052712311062600_bib73","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1161\/HYPERTENSIONAHA.116.08526","article-title":"Nonsteroidal mineralocorticoid receptor antagonist finerenone protects against acute kidney injury-mediated chronic kidney disease","volume":"69","author":"Lattenist","year":"2017","journal-title":"Hypertension"},{"key":"2025052712311062600_bib74","doi-asserted-by":"publisher","first-page":"e0184888","DOI":"10.1371\/journal.pone.0184888","article-title":"The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury","volume":"12","author":"Dutzmann","year":"2017","journal-title":"PLoS ONE"},{"key":"2025052712311062600_bib75","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"key":"2025052712311062600_bib76","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1159\/000503713","article-title":"Design and baseline characteristics of the finerenone in reducing kidney failure and disease progression in diabetic kidney disease trial","volume":"50","author":"Bakris","year":"2019","journal-title":"Am J Nephrol"},{"key":"2025052712311062600_bib77","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1159\/000503712","article-title":"Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial","volume":"50","author":"Ruilope","year":"2019","journal-title":"Am J Nephrol"},{"key":"2025052712311062600_bib78","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","article-title":"Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"394","author":"Agarwal","year":"2019","journal-title":"Lancet North Am Ed"},{"key":"2025052712311062600_bib79","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"2025052712311062600_bib80","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.110908","article-title":"Rationale and design of a randomised Phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: the FINE-ONE trial","volume":"204","author":"Heerspink","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"2025052712311062600_bib81","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03264-4","article-title":"Finerenone in Heart failure and Chronic Kidney disease with type 2 Diabetes: the FINE-HEART pooled analysis of cardiovascular, kidney, and mortality outcomes","volume":"30","author":"Vaduganathan","year":"2024","journal-title":"Nat Med"},{"key":"2025052712311062600_bib82","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1002\/ejhf.2386","article-title":"Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial","volume":"24","author":"Butler","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2025052712311062600_bib83","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ekir.2021.10.008","article-title":"Finerenone in predominantly advanced CKD and type 2 diabetes with or without sodium-glucose cotransporter-2 inhibitor therapy","volume":"7","author":"Rossing","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2025052712311062600_bib84","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1159\/000516213","article-title":"Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage","volume":"52","author":"Kolkhof","year":"2021","journal-title":"Am J Nephrol"},{"key":"2025052712311062600_bib85","volume-title":"A Parallel-Group Treatment, Phase 2, Double-Blind, Three-Arm Study to Assess Efficacy and Safety of Finerenone plus Empagliflozin Compared with either Finerenone or Empagliflozin Alone in Participants with Chronic Kidney Disease and Type 2 Diabetes","author":"Bayer","year":"2023"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfae346\/60781420\/sfae346.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/1\/sfae346\/60781420\/sfae346.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/1\/sfae346\/60781420\/sfae346.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T12:31:40Z","timestamp":1748349100000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfae346\/7906595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,21]]},"references-count":85,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,7]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfae346","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,11,21]]},"article-number":"sfae346"}}